Abstract library

12 results for "Granberg".
#173 Temozolomide in Metastatic Bronchial Carcinoids
Introduction: Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment thus far have been disappointing. Temozolomide has, however, shown some activity in a small prior study.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel P Lindholm
#178 Treatment with 177Lutetium-DOTA-Tyr3-octreotate in Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors express somatostatin receptors. Treatment with radiolabelled somatostatin analogs has been used for more than 10 years. Useful isotopes are 111Indium, 99Yttrium and 177Lutetium.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ass Prof Dan Granberg
#196 Efficacy and Safety of the Combination Streptozotocin, 5-FU in Endocrine Pancreatic Tumors: A Retrospective Study
Introduction: The combination of Streptozotocin with 5-FU has been used during the past decades in our institution as the first-line treatment in pancreatic NETs with low to moderate proliferation.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Pantelis Antonodimitrakis
#209 A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional
Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Anders Öhberg
#247 Carcinoid Metastases to the Breast: More Common than Previously Thought. A Presentation of 13 Cases
Introduction: Metastases from carcinoid tumors to the breast have been described as a rare phenomenon. Presentation and cytopathologic findings of these tumors can closely mimic that of a mammary carcinoma.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Joakim Crona
#434 Treatment, Survival and Prognostic Markers in Patients with Thymic Carcinoids: A Clinicopathologic Study of 28 Cases
Introduction: Thymic carcinoids are uncommon but malignant tumors, usually associated with a poor prognosis. The number of cases reported is limited to a few hundred and there are few prognostic factors available.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Joakim Crona
#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP
Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Gordana Kozlovacki
#503 Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1
Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Jenny Falkerby
#658 Somatic Mutations in H-RAS in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing.
Introduction: Up to 60% of pheochromocytoma (PCC) and paraganglioma (PGL) are associated with mutations in established PCC and PGL susceptibility loci. A majority of unexplained cases are characterized by an increased activity of the RAS/RAF/ERK signalling pathway. Mutations in RAS subtypes H, K and N are common in human cancers, however, previous studies have been inconsistent regarding the mutational status of RAS in PCC and PGL.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Joakim Crona
#861 Targeted Next Generation Sequencing in the Screening for Familial Neuroendocrine Tumor Syndromes: A Tool for Personalized Medicine
Introduction: Multiple syndromes are described as conferring susceptibility to NETs; MEN1 & 2, NF1, familial PGL 1-5, TSC, VHL and germline mutations in the HIF2A, MAX, or TMEM127. Genetic testing covering these diagnoses may be extensively resource-demanding using traditional techniques due to the large extent of these loci.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Joakim Crona